Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.
In a double-blind randomized trial, we evaluated the efficacy and safety of three oral dosage regimens of fleroxacin, a new fluoroquinolone, once daily in 62 patients for the treatment of complicated urinary tract infections. The regimens compared were 200 mg for 10 days (n = 20), 400 mg for 10 days...
保存先:
| 出版年: | Antimicrob Agents Chemother |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology (ASM)
1990
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC171606/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2110437/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.34.3.409 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|